Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
17.3.2025 19:00:00 CET | Business Wire | Press release
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative.
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms4.3.2026 16:12:00 CET | Press release
Armis CentrixTM leveraged by global organizations to manage cyber risk across their entire attack surface Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year. “In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.” Armis was named a Leader in this report among the 13 vendor
Svante Acquires Carbon Dioxide Removal Project Developer, Carbon Alpha Corp.4.3.2026 16:00:00 CET | Press release
Svante acquires Carbon Alpha to accelerate commercial-scale carbon removal & expand its CCS/BECCS project development business in Western Canada. Acquisition adds the North Star BECCS Project, developed in partnership with the Meadow Lake Tribal Council, advancing the market for durable and verifiable CDR credits. The transaction strengthens Svante’s fully integrated carbon management platform, adding CO₂ storage expertise, a regional pipeline & a major geological storage hub. Svante Technologies Inc. (Svante), a leader in carbon management, and Calgary-based Carbon Alpha Corporation (Carbon Alpha) today announced that Svante has acquired Carbon Alpha and its related subsidiaries, including Carbon Alpha Development Corp. and its ownership interests in North Star Carbon Solutions Corp. and North Star Carbon Solutions Limited Partnership, a project developer for carbon capture and storage (CCS) in Western Canada. With this transaction, Carbon Alpha’s flagship North Star Bioenergy Carbon
Binarly Announces Leadership Transition as Enterprise Demand Accelerates for Supply-Chain Security4.3.2026 16:00:00 CET | Press release
Binarly, the industry leader in software and firmware supply‑chain security, today announced a leadership transition as the company enters its next phase of growth. Founder and current CEO Alex Matrosov has joined the company’s Board, and Gwenyth Castro has joined as Chief Executive Officer to scale global go-to-market and enterprise growth. Binarly developed its Transparency Platform on a unique, patented technology core designed to help the world’s largest enterprises identify and reduce third-party software risk across complex environments. The platform is trusted by organizations including Meta and Dell, among others. “We built Binarly to solve a problem the industry kept ignoring: you can’t secure what you can’t see,” said Alex Matrosov, Founder of Binarly. “Over the last five years, this team turned deep program analysis and vulnerability research into a platform trusted by some of the world’s most demanding enterprises. Now, as AI accelerates how software is built and shipped, t
Unleash Raises $35M Led by One Peak to Help Enterprises Ship AI-driven Software Faster, Safer, and Smarter4.3.2026 15:00:00 CET | Press release
Unleash, the open-source FeatureOps company, today announced a $35 million Series B financing led by One Peak, with participation from existing investors Spark Capital, Frontline Ventures, and Firstminute Capital. The new funding will be used to accelerate product innovation and global expansion as enterprises confront the opportunities and risks of AI-accelerated software delivery. AI has dramatically accelerated software development, creating a generational opportunity for anyone in an enterprise to turn ideas, prompts, and prototypes into applications. But AI has also outpaced the systems designed to control software delivery. DORA research shows that a 25% rise in AI adoption correlates with a 7% drop in software stability. Enterprises are shipping code 2-3x faster with AI, yet outages caused by uncontrolled feature rollouts and missing kill switches are costing businesses millions in lost revenue, prolonged customer downtime, and brand damage. FeatureOps is emerging as the missing
Capcom’s Resident Evil Requiem Surpasses 5 Million Units!4.3.2026 15:00:00 CET | Press release
– Worldwide acclaim contributed to strong sales – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, surpassed 5 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304446142/en/ Resident Evil Requiem Logo Resident Evil Requiem is the latest installment in the Resident Evil series, which celebrates its 30th anniversary this month. The title successfully elevated the essence of survival horror by heightening the interplay between intense fear and exhilarating action. Resident Evil Requiem was developed using RE ENGINE, Capcom’s proprietary game engine, which allowed the company to deliver visuals in photorealistic detail, including the characters’ skin, teary eyes, and flowing hair, as well as the translucency of light. In addition, the title offers a new game experience for a broad fanbase through multiple difficulty settings that accommoda
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom